Several clinical trials utilizing imaging-based assessments have demonstrated significant reductions in visceral fat volume among patients treated with GLP-1 agonists
Together, this evidence suggests that GIP may drive WL directly, inhibiting caloric intake, indirectly exploiting the anorectic action of GLP-1, or by reducing GLP-1RA adverse effects (59, 60, 63)
This differs from dual agonists like tirzepatide, which activate GLP-1 and GIP only
The short-chain fatty acid (SCFA) butyrate, which is produced by the microbial fermentation of dietary fiber in the large intestine, has been shown to have multiple beneficial effects in mammals 4,5,6,7,8,9
This multi-disciplinary synergy ensures that all aspects of your health are considered, leading to more comprehensive and sustainable GLP-1 therapy results
A licensed provider reviews it and, if appropriate, creates a treatment plan and writes a prescription - brand-stated at within one day